semaglutide india injection Ozempic 0.5mg (Semaglutide) | GLP-1 Agonist for Type 2 Diabetes Control Semaglutide (Ozempic) Guide for Indian
Description
Key considerations if a patient discloses combined use include: Gastrointestinal effects : Both agents may independently cause nausea, vomiting, or appetite suppression
K., Heilmann C
This is important particularly for patients undergoing significant facial changes
The study design did not include a control group of post-bariatric patients not using semaglutide for comparison
Patients with active inflammatory bowel disease flare-ups (though data is limited)
Compounded medications are not approved by the FDA
